LQDA Liquidia Corporation Stock Quote

LQDA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.12	Insider Own	14.70%	Shs Outstand	37.76M	Perf Week	-3.28%
Market Cap	130.33M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-13.07%	Shs Float	35.53M	Perf Month	-4.53%
Income	-58.20M	PEG	-	EPS next Q	-0.37	Inst Own	43.70%	Short Float	3.83%	Perf Quarter	-13.49%
Sales	0.00M	P/S	-	EPS this Y	24.60%	Inst Trans	-0.14%	Short Ratio	1.33	Perf Half Y	-56.36%
Book/sh	1.73	P/B	1.71	EPS next Y	31.40%	ROA	-93.80%	Target Price	-	Perf Year	-56.10%
Cash/sh	1.80	P/C	1.64	EPS next 5Y	-	ROE	-177.80%	52W Range	2.53 - 12.10	Perf YTD	0.00%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-88.30%	52W High	-75.29%	Beta	-
Dividend %	-	Quick Ratio	5.70	Sales past 5Y	-	Gross Margin	-	52W Low	18.18%	ATR	0.17
Employees	64	Current Ratio	5.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.65	Volatility	4.41% 6.02%
Optionable	Yes	Debt/Eq	0.20	EPS Q/Q	44.60%	Profit Margin	-	Rel Volume	1.01	Prev Close	2.95
Shortable	Yes	LT Debt/Eq	0.10	Earnings	Nov 06 AMC	Payout	-	Avg Volume	1.02M	Price	2.99
Recom	2.20	SMA20	1.51%	SMA50	-5.85%	SMA200	-45.84%	Volume	1,028,270	Change	1.36%

Dec-04-20

Initiated

H.C. Wainwright

Buy

Nov-20-20

Downgrade

Wedbush

Outperform → Neutral

$20 → $4

Nov-08-18

Resumed

Jefferies

Buy

Sep-05-18

Initiated

Wedbush

Outperform

$26

Aug-20-18

Initiated

Needham

Buy

$30

Aug-20-18

Initiated

Jefferies

Buy

$22

Jan-04-21 03:11PM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Liquidia Corporation (LQDA) Investors of Investigation ACCESSWIRE
Dec-31-20 04:21PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
12:47PM	EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Liquidia Corporation LQDA Business Wire
Dec-23-20 12:40AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA ACCESSWIRE
Dec-20-20 12:05AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA GlobeNewswire
Dec-16-20 04:42PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA Newsfile
Dec-14-20 09:28AM	Liquidia Corporation Announces Chief Executive Officer Transition GlobeNewswire
02:39AM	Health Check: How Prudently Does Liquidia (NASDAQ:LQDA) Use Debt? Simply Wall St.
Dec-12-20 08:13PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA GlobeNewswire
Dec-10-20 09:10PM	Is LQDA A Good Stock To Buy Now? Insider Monkey
Dec-09-20 11:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA ACCESSWIRE
Dec-07-20 08:22PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA GlobeNewswire
Dec-05-20 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA ACCESSWIRE
Nov-30-20 08:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Liquidia Corporation LQDA GlobeNewswire -7.92%
08:49PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA GlobeNewswire
07:15AM	Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer GlobeNewswire
Nov-29-20 07:45AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA ACCESSWIRE
Nov-26-20 09:14AM	Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter Zacks
Nov-25-20 11:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA PR Newswire -5.16%
07:35AM	The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga
07:00AM	Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension GlobeNewswire
Nov-24-20 08:12AM	The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga
Nov-22-20 07:22AM	The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates Benzinga
Nov-18-20 04:01PM	Liquidia Closes Acquisition of RareGen GlobeNewswire
Nov-16-20 07:15AM	Liquidia Announces Results of Special Meeting of Stockholders GlobeNewswire -7.89%
Nov-12-20 10:06AM	Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference GlobeNewswire -13.79%
Nov-09-20 07:15AM	Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
06:15AM	Liquidia Technologies, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 07:15AM	Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC GlobeNewswire -27.71%
Oct-30-20 08:40PM	UPDATE Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020 GlobeNewswire
04:15PM	Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020 GlobeNewswire
Oct-19-20 02:50PM	Why Liquidia's Stock Is Trading Higher Today Benzinga +19.23%
08:30AM	Liquidia Announces Postponement of Special Meeting of Stockholders GlobeNewswire
Oct-14-20 09:25AM	Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics Tyvaso® Patents GlobeNewswire -18.14%
Oct-05-20 07:15AM	Liquidia Names Gerald M. OBrien, MD, as Vice President, Pulmonary Clinical Development GlobeNewswire
Sep-17-20 07:15AM	Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC GlobeNewswire
Sep-14-20 01:04PM	When Will Liquidia Technologies, Inc. (NASDAQ:LQDA) Become Profitable? Simply Wall St. +6.97%
Aug-28-20 07:15AM	Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil GlobeNewswire
Aug-20-20 09:15AM	Liquidia Announces Chief Financial Officer Transition GlobeNewswire +6.42%
Aug-10-20 07:15AM	Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-20 05:30PM	Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire +5.27%
07:15AM	Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting GlobeNewswire
Aug-03-20 09:20AM	Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020 GlobeNewswire +5.24%
Jul-24-20 09:08AM	Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent GlobeNewswire -8.58%
Jul-08-20 10:35PM	SHAREHOLDER ALERT: Halper Sadeh LLP Announces It is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm PR Newswire
Jul-02-20 04:01PM	Liquidia Announces Closing of Public Offering of Common Stock GlobeNewswire -5.92%
Jun-30-20 07:41AM	The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test Benzinga -21.09%
Jun-29-20 10:45PM	Liquidia to Host Conference Call to Provide Update on Recent Announcements GlobeNewswire
10:30PM	Liquidia Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:05PM	Liquidia Announces Proposed Offering of Common Stock GlobeNewswire
04:01PM	Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH GlobeNewswire
Jun-16-20 08:20AM	Is Liquidia Technologies (NASDAQ:LQDA) Using Debt In A Risky Way? Simply Wall St. +5.39%
Jun-12-20 07:09PM	Do Hedge Funds Love Liquidia Technologies, Inc. (LQDA)? Insider Monkey
Jun-05-20 03:30PM	Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents GlobeNewswire -20.08%
May-29-20 10:31AM	Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne Zacks
May-27-20 08:04PM	Liquidia to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-22-20 10:01AM	Why Liquidia Technologies (LQDA) Stock Might be a Great Pick? Zacks +5.50%
May-18-20 07:15AM	Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer GlobeNewswire +7.87%
May-11-20 04:01PM	Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +9.59%
May-07-20 09:30AM	These 3 Biotech Stocks Have Massive Upside Potential, Says Wedbush TipRanks +9.81%
May-06-20 06:30PM	Liquidia to Report First Quarter 2020 Financial Results and Provide Corporate Update on May 11, 2020 GlobeNewswire -10.20%
Apr-30-20 07:30AM	Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension GlobeNewswire -11.70%
Apr-09-20 07:30AM	Liquidia to Present at the 19th Annual Needham Healthcare Conference GlobeNewswire
Apr-08-20 07:45AM	Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension GlobeNewswire +17.07%
Mar-11-20 08:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:00AM	Liquidia Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Mar-04-20 12:30PM	Will Liquidia Technologies, Inc. (LQDA) Report Negative Earnings Next Week? What You Should Know Zacks +15.10%
Feb-26-20 04:30PM	Liquidia to Report 2019 Financial Results and Provide Corporate Update on March 11, 2020 GlobeNewswire
04:30PM	Liquidia to Present at Cowen 40th Annual Health Care Conference GlobeNewswire
Jan-27-20 02:55PM	Liquidia seeks pivotal FDA approval for lead drug American City Business Journals -8.13%
08:00AM	Liquidia Submits New Drug Application for LIQ861 (treprostinil) inhalation powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension (PAH) GlobeNewswire
Jan-24-20 09:00AM	Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI) GlobeNewswire -8.81%
Jan-15-20 07:29AM	Will Liquidia Continue to Surge Higher? Zacks +13.96%
Dec-26-19 02:55PM	Liquidia nets $22.4 million as it moves forward with lead drug American City Business Journals +43.47%
10:32AM	Liquidia Technologies stock soars after Wedbush says private placement gives company runway through Q4 2020 MarketWatch
Dec-24-19 08:30AM	Liquidia Technologies Announces $22.4 Million Private Placement GlobeNewswire +12.46%
Dec-20-19 06:21PM	Is Liquidia Technologies, Inc. (LQDA) A Good Stock To Buy? Insider Monkey
Nov-13-19 08:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates Zacks +8.45%
07:00AM	Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
06:00AM	Liquidia Technologies, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-19 08:00AM	Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019 GlobeNewswire -14.59%
Nov-01-19 08:00AM	Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors GlobeNewswire +7.08%
Oct-23-19 10:33AM	Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +7.43%
Oct-22-19 10:52AM	Is Liquidia Technologies (NASDAQ:LQDA) Using Too Much Debt? Simply Wall St.
Sep-25-19 04:05PM	Liquidia to Present at Cantor 2019 Global Healthcare Conference GlobeNewswire
Sep-12-19 04:05PM	Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors GlobeNewswire
Sep-03-19 07:00AM	Liquidia to Present at H.C. Wainwright Healthcare Conference GlobeNewswire -18.97%
Aug-27-19 02:44PM	Morrisville's Liquidia seeks partner as it prepares to launch new drug American City Business Journals -17.57%
Aug-08-19 04:05PM	Liquidia to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire +9.60%
07:00AM	Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-02-19 09:00AM	Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019 GlobeNewswire -6.62%
Jul-24-19 01:01PM	Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price? Simply Wall St.
Jun-28-19 08:35PM	Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA) Insider Monkey
02:17PM	Behind Liquidia's new deal with GSK American City Business Journals
Jun-26-19 04:15PM	Liquidia and GSK Restructure Collaboration Agreement GlobeNewswire -5.01%
Jun-05-19 04:05PM	Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019 GlobeNewswire
Jun-03-19 08:30AM	Liquidia to Present at Jefferies Healthcare Conference GlobeNewswire
May-22-19 04:30PM	Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer GlobeNewswire
May-14-19 04:15PM	Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019 GlobeNewswire

Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eshelman Ventures, LLC	10% Owner	Jan 15	Sale	3.01	27,000	81,251	6,058,149	Jan 19 05:20 PM
Eshelman Ventures, LLC	10% Owner	Jan 14	Sale	3.02	34,466	103,918	6,085,149	Jan 15 05:44 PM
Eshelman Ventures, LLC	10% Owner	Jan 13	Sale	3.07	3,393	10,416	6,119,615	Jan 15 05:44 PM
Eshelman Ventures, LLC	10% Owner	Jan 12	Sale	3.06	99,335	304,402	6,123,008	Jan 13 06:00 PM
Eshelman Ventures, LLC	10% Owner	Jan 11	Sale	3.05	13,524	41,250	6,222,343	Jan 13 06:00 PM
Eshelman Ventures, LLC	10% Owner	Jan 08	Sale	3.08	71,902	221,508	6,235,867	Jan 11 05:50 PM
Eshelman Ventures, LLC	10% Owner	Jan 07	Sale	3.12	142,819	445,638	6,307,769	Jan 11 05:50 PM
Eshelman Ventures, LLC	10% Owner	Dec 22	Sale	3.14	7,949	24,960	6,450,588	Dec 28 05:20 PM
Eshelman Ventures, LLC	10% Owner	Dec 21	Sale	3.13	51,906	162,466	6,458,537	Dec 22 07:08 PM
Eshelman Ventures, LLC	10% Owner	Dec 18	Sale	3.14	53,309	167,470	6,510,443	Dec 22 07:08 PM
Eshelman Ventures, LLC	10% Owner	Dec 14	Sale	3.13	6,417	20,085	6,563,752	Dec 16 05:11 PM
Eshelman Ventures, LLC	10% Owner	Nov 30	Sale	3.13	200	626	6,570,169	Dec 01 08:56 PM
Eshelman Ventures, LLC	10% Owner	Nov 27	Sale	3.13	200	626	6,570,369	Dec 01 08:56 PM
Eshelman Ventures, LLC	10% Owner	Nov 25	Sale	3.13	17,364	54,349	6,570,569	Dec 01 08:34 PM
Eshelman Ventures, LLC	10% Owner	Nov 24	Sale	3.15	283,465	894,247	6,587,933	Dec 01 08:34 PM
Eshelman Ventures, LLC	10% Owner	Nov 23	Sale	3.16	133,346	421,347	6,871,398	Dec 01 08:34 PM
Eshelman Ventures, LLC	10% Owner	Nov 19	Sale	3.35	30,000	100,500	7,004,744	Dec 01 08:34 PM
Eshelman Ventures, LLC	10% Owner	Jul 02	Buy	8.00	1,875,000	15,000,000	7,034,744	Jul 02 07:31 PM
Maynor Benjamin	SVP, Research and Development	May 27	Option Exercise	2.69	4,754	12,788	11,735	May 28 04:30 PM
Maynor Benjamin	SVP, Research and Development	Apr 14	Option Exercise	1.85	6,132	11,344	10,300	Apr 16 04:30 PM
Eshelman Ventures, LLC	10% Owner	Apr 06	Buy	5.28	44,250	233,715	175,573	Apr 07 05:18 PM
Eshelman Ventures, LLC	10% Owner	Apr 03	Buy	4.85	35,000	169,740	131,323	Apr 07 05:18 PM
Eshelman Ventures, LLC	10% Owner	Apr 02	Buy	4.96	7,223	35,792	96,323	Apr 03 05:40 PM
Eshelman Ventures, LLC	10% Owner	Apr 01	Buy	4.89	45,000	220,122	89,100	Apr 03 05:40 PM
Eshelman Ventures, LLC	10% Owner	Mar 31	Buy	4.87	30,000	146,112	44,100	Apr 01 05:35 PM
Eshelman Ventures, LLC	10% Owner	Mar 30	Buy	4.76	14,100	67,106	14,100	Apr 01 05:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience